ADTX - Aditxt, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

ADTX

ADITXT, INC.

OTC

$0.01

▲ UP 20.69% (0.00)

KEY STATISTICS

Market Cap$6.99 M

52w High$27092.88

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume30.52M

Shares Out.997.98M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jeffrey Busch

COMPENSATION 2026

Salary$500,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$500,000

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 30, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$1280.00

Target Low$1280.00

Target Median$1280.00

Target Consensus$1280.00

UPCOMING EARNINGS

DateSep 2, 2026

DayWednesday

Rev. Est.$1.00M

SEP

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-05-18	Reverse	1:27
2026-03-09	Reverse	1:8
2025-11-03	Reverse	1:113
2025-03-17	Reverse	1:250
2024-10-02	Reverse	1:40
2023-08-18	Reverse	1:40
2022-09-14	Reverse	1:50

PRICE

$0.01 ▲ UP 20.69% (+$0.00)

OVERLAYS

About Aditxt, Inc.

https://www.aditxt.com ↗

Aditxt, Inc. is a biotech firm focused on immune health, developing immune monitoring tools like AditxtScore and therapies such as Apoptotic DNA Immunotherapy for transplantation, autoimmune diseases, and allergies.

INDUSTRY

Biotechnology

A PRODUCT ADITXT, INC. IS KNOWN FOR

Mitomic® Endometriosis Test (MET™)

Pearsanta's MET™ is a blood-based, non-invasive diagnostic test for early detection of endometriosis, aiming to reduce diagnostic delays and enable earlier intervention for a condition affecting one in ten women worldwide.